Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
\-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- \-- Conference call today at 8:30 a.m. ET --PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative
GlobeNewswire · 2天前
Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 9:10 AM ET on Tuesday, August 11, 2020. Live audio of the virtual even
GlobeNewswire · 2天前
Pacira Highlights Publication Of Phase 4 Study Of EXPAREL In Cesarean Section Procedures In Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery – PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira
Benzinga · 3天前
Pacira Highlights Publication Of Phase 4 Study Of EXPAREL In Cesarean Section Procedures In Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery – PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira
Benzinga · 3天前
Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full res
GlobeNewswire · 3天前
FDA accepts Pacira's supplement application for expanded use of EXPAREL for postoperative pain
The FDA has accepted for review Pacira BioSciences' (PCRX +0.1%) supplemental marketing application seeking expansion of EXPAREL (bupivacaine liposome inje
seekingalpha · 3天前
Pacira BioSciences Announces FDA Acceptance Of sNDA For EXPAREL Use In Pediatric Patients
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over PARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
Benzinga · 4天前
Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and overPARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and D